Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487565 | 0.80 | ALDH1A1 (0.37) | TDP1 | |
| SCHEMBL15164060 | 0.80 | LMNA (0.39) | TDP1L3MBTL1 | |
| SCHEMBL26640966 | 0.78 | PLAU (0.43) | TDP1L3MBTL1 | |
| SCHEMBL487536 | 0.78 | CHRNB2 (0.36) | — | |
| SCHEMBL30648735 | 0.78 | PLAU (0.43) | TDP1L3MBTL1 | |
| SCHEMBL15164059 | 0.77 | CHRNB2 (0.39) | CPB2CYP4F2CYP4A11 | |
| SCHEMBL23530950 | 0.77 | AGBL2 (0.37) | TDP1L3MBTL1 | |
| SCHEMBL24424856 | 0.77 | CCR1 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL29674728 | 0.77 | AGBL2 (0.37) | TDP1L3MBTL1 | |
| SCHEMBL25090903 | 0.72 | HTT (0.42) | TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | AURKA, AURKC, AURKB | CPB2 4028/4885CYP4F2 3969/4885CYP4A11 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.